Industry News

UnitedHealth Group's free-standing pharmacy care services business. The new jobs include bilingual customer service roles."/>
United Health's pharmacy division OptumRx to hire 120 in Costa Mesa [The Orange County Register]
Healthways, Inc. today announced that its financial results for the third quarter ending September 30, 2016, will be released after market close on Tuesday, November 1, 2016, followed the same day by a conference call and live webcast scheduled for 5:00 p.m. The live broadcast of Healthways’ quarterly conference call will be available online by going to and clicking on“ Investors. "For those who cannot listen to the live broadcast,..."/>
Healthways to Issue Third Quarter 2016 Financial Results After Market Close on November 1
Kitov Pharmaceuticals Holdings Ltd., an innovative biopharmaceutical company focused on late stage drug development, announced today that its lead drug candidate KIT-302 has successfully completed an additional pharmacokinetic bioequivalence study and once more successfully met the U.S. Food and Drug Administration's standards for establishing bioequivalence to the reference drugs."/>
Kitov Reports Successful Results for Additional KIT-302 Pharmacokinetic Bioequivalence Study
PAREXEL International Corporation, a leading global biopharmaceutical services provider, today announced that the Company has entered into a definitive agreement to acquire ExecuPharm, Inc., a leading, global functional service provider serving the biopharmaceutical industry. The acquisition is expected to close in the next three weeks. Terms of the transaction were not disclosed."/>
PAREXEL ANNOUNCES EXECUTION OF DEFINITIVE AGREEMENT TO ACQUIRE EXECUPHARM; Acquisition will strengthen and add scale to current functional services offering to meet growing demand
ReWalk Robotics Ltd over alleged Securities Laws violations by ReWalk Robotics Ltd in connection the company’ s September 12, 2014 initial public offering. Investors who purchased shares of ReWalk Robotics Ltd have certain options and should contact the Shareholders Foundation at or call +1 779- 1554.."/>
Lawsuit for Investors in ReWalk Robotics Ltd (NASDAQ:RWLK) shares announced by Shareholders Foundation
Theratechnologies Inc. announced today that it will issue its financial results for the third quarter ended August 31, 2016, on Tuesday, October 4, 2016, before markets open. A conference call will be held the same day at 8:30 a.m. to discuss the results. The call will be hosted by Luc Tanguay, President and Chief Executive Officer."/>
Theratechnologies to Announce Financial Results for the Third Quarter of 2016
Cigna today announced new, expanded access and choice to affordable telehealth services for millions of Americans enrolled in Cigna administered medical and behavioral health plans for 2017.. In 2017, Cigna will significantly expand its telehealth coverage by adding AMWELL to its existing offering of MDLIVE– both as a standard telehealth benefit for most* of Cigna’ s U.S. employer-sponsored group health plans, as well as..."/>
Cigna Telehealth Connection Expands Access and Choice to Millions, Including Adding Access to Behavioral Health Consults
Premier Biomedical, Inc. announced today their newly created joint venture company, Premier Biomedical Pain Management Solutions, LLC has manufactured and shipped initial design sample pain relieving topical patches for distribution to select VA hospital patients, military personnel, doctors, and professional sports figures. These patent-pending, opioid- and narcotic-free all-natural-ingredient topical pain relief patches consist of a..."/>
Premier Biomedical Pain Management Solutions Announces Shipment of Initial Samples of Opioid-Free, 50-State Legal, CBD-Based Pain-Relieving Topical Patch
Humana Inc. has ranked No. 4 on the list of the“ Healthiest 100 Workplaces in America,” compiled by Healthiest Employers to honor organizations that have comprehensively incorporated the most vital corporate wellness policies, practices and programs in their workplaces. This Smart News Release features multimedia."/>
Humana ranks No. 4 among the Healthiest 100 Workplaces in America
Aetna today announced a new initiative to revolutionize members’ consumer health experience by combining the power of iOS apps and the unmatched user experience of Apple products including Apple Watch, iPhone and iPad with Aetna’ s analytics-based wellness and care management programs. Beginning this fall, Aetna will make Apple Watch available to select large employers and individual customers during..."/>
Aetna to Transform Members’ Consumer Health Experience Using iPhone, iPad and Apple Watch
Rich Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing innovative therapies in oncology, announced today several of the milestones it had reached during the past quarter, and those that it intends to pursue in the upcoming quarters. Received clearance from the U.S. Food and Drug Administration to commence its Phase 1/ 2 clinical trials for the treatment of Acute Myelocytic Leukemia and..."/>
Rich Pharmaceuticals, Inc. Announces Quarterly Milestones
Precision Optics Corporation, Inc. announced that it intends to release its financial results for the fiscal year ended June 30, 2016 on Wednesday, September 28, 2016.. Management has scheduled a conference call for 9:00 a.m. ET on Thursday, September 29 th to review the Company's financial results and future outlook. Participants may dial into the following number to access the call: 1-866-652-5200 or 1-412-317-6060. Please ask to be joined into..."/>
Precision Optics Corporation Schedules Fiscal Year End Conference Call
RepliCel Life Sciences Inc., a clinical-stage regenerative medicine company focused on the development of autologous cell therapies, is pleased to announce its intention to settle debt in the aggregate amount of $374,071.63 owed by the Company to certain creditors by the issuance of 719,368 units. Each Unit consists of one common share of the Company and one share purchase warrant, with each Warrant entitling the holder to purchase one..."/>
RepliCel Announces Debt Settlement
Neogen Corporation announced today that revenues for the first quarter of its 2017 fiscal year, which ended Aug. 31, were $83,645,000— a 12% increase compared to revenues of $74,860,000 in the first quarter of last year. First quarter net income increased 6% to $9,881,000, or $0.26 per share, from the previous year's first quarter income of $9,323,000, or $0.25 a share. The revenues and net income represent first quarter records for the 34-..."/>
Neogen reports 12% revenue increase
DarioHealth Corp., a leader in digital health and mobile health solutions and the developer of the Dario™ Smart Diabetes Management Solution, today announced the launch of an online store in Canada. This is in collaboration with A&D Medical, a global leader in connected health and biometric measurement devices and services, and Bayshore Specialty Rx Ltd.' s online pharmacy Diabetes Express. While Dario is widely accepted under reimbursement in..."/>
DarioHealth Launches New Digital Platform and Online Store in Canada
ANI Pharmaceuticals, Inc. today announced the launch of Erythromycin Ethylsuccinate for Oral Suspension 200 mg/5mL indicated as a treatment for various infections. The current annual U.S. market for this product is approximately $78 million, according to IMS Health, and is representative of two brand products. ANI will immediately launch the product."/>
ANI Pharmaceuticals Announces Launch of Erythromycin Ethylsuccinate for Oral Suspension, 200mg/5mL
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company's Chief Executive Officer, will present at the Leerink Partners Roundtable Series: Rare Disease& Immuno-Oncology on Wednesday, September 28, 2016, at 2:35 pm ET in New York.. The live and archived webcast of the company presentation will be accessible from..."/>
Ultragenyx to Present at Leerink Partners Roundtable Series
OPKO Health, Inc., announces the appointment of Benjamin D. Solomon, M.D. as Managing Director of GeneDx, effective as of October 3, 2016. GeneDx, part of OPKO’ s BioReference Laboratories subsidiary, specializes in genetic testing for rare hereditary disorders. Solomon is a pediatric geneticist who focuses on the use of genetics and genomics to identify, understand and care for patients with both rare and common genetic conditions."/>
OPKO Health Appoints Dr. Benjamin Solomon as Managing Director of GeneDx

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Information Technology553 Articles
Consumer Discretionary487 Articles
Financials315 Articles
Industrials312 Articles
Health Care277 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at